Sunovion and PsychoGenics unveiled positive phase 2 results for a new schizophrenia treatment that does not bind to the brain’s dopamine receptors.

Amag Pharma has struck a merger deal with Perosphere, adding an anticoagulant reversal agent in midstage trials to its emerging hematology business.

Applied Genetic Technologies’ $1 billion-plus gene therapy pact with Biogen has been torn up after their lead candidate failed a phase 1/2 trial.

Shareholders had accused Biofrontera of acting contrary to its duties when it priced and sold stock in the U.S.

With the FDA approving 55 NMEs over the first 11 months of the year, 2018 has eased past 1996 to become the busiest year ever.

The small phase 2 feasibility study linked fixed-dose combination NRX-101 to improved scores on a depression rating scale.

Scientists have early evidence that Amgen's oncolytic virus plus PD-1 and MEK inhibitors could be effective in treating melanoma.

GenSight has new data from its phase 3 program for its gene therapy for rare eye disease LHON, sparking another rise in its share price.

Akero will push a nonalcoholic steatohepatitis treatment licensed from Amgen through phase 2, and expand its pipeline.

The appointment means Gentile will commit full time to the autophagy startup he helped get off the ground.